» Articles » PMID: 16531981

Chemical and Hormonal Determinants of Vascular Calcification in Vitro

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2006 Mar 15
PMID 16531981
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular calcification is a complex process that is dependent not only on the physicochemical effects of Ca, PO(4), and pH, but also on smooth muscle factors that may be regulated by these ions as well as by 1,25-dihydroxyvitamin D(3) (calcitriol) and parathyroid hormone (PTH). These minerals and hormones were tested in a model of medial calcification in rat aorta maintained in culture for 9 days. Calcification was quantitated as incorporation of (45)Ca, alkaline phosphatase activity was measured in aortic homogenates, and osteopontin production was measured from immunoblots of culture medium. At 1.8 mM Ca (1.46 mM free), calcification occurred at or above 2.8 mM PO(4). At 3.8 mM PO(4), calcification occurred at or above 1.10 mM free [Ca]. At a constant [Ca] x [PO(4)], calcification varied directly with [Ca] and inversely with [PO(4)]. Calcification was directly related to pH between 7.19 and 7.50 but not altered by PTH or calcitriol. Alkaline phosphatase activity and osteopontin production were increased by Ca, PO(4), calcitriol, and PTH. We conclude that calcification of rat aorta in vitro requires elevation of both [Ca] and [PO(4)], and that [Ca] rather than [PO(4)] or the product of the two is the dominant determinant. The induction of alkaline phosphatase and osteopontin indicates that Ca and PO(4) have effects in addition to simple physicochemical actions. Although PTH and calcitriol did not increase calcification in vivo, they have effects on smooth muscle that could influence calcification in vivo. Calcification is enhanced by alkalinity within the range produced during hemodialysis.

Citing Articles

Lead Acetate-Injected Mice is an Animal Model for Extrapolation of Calcifying Response to Humans Due to Low Involvement of Bone Resorption.

Morikane S, Ishida K, Ashizawa N, Taniguchi T, Matsubayashi M, Kurita N Calcif Tissue Int. 2024; 115(3):315-327.

PMID: 38951181 DOI: 10.1007/s00223-024-01245-w.


Hemodialysis Procedures for Stable Incident and Prevalent Patients Optimize Hemodynamic Stability, Dialysis Dose, Electrolytes, and Fluid Balance.

Stuard S, Ridel C, Cioffi M, Trost-Rupnik A, Gurevich K, Bojic M J Clin Med. 2024; 13(11).

PMID: 38892922 PMC: 11173331. DOI: 10.3390/jcm13113211.


Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects.

Raphael K Int J Mol Sci. 2024; 25(10).

PMID: 38791238 PMC: 11121226. DOI: 10.3390/ijms25105187.


Effects of correcting metabolic acidosis on muscle mass and functionality in chronic kidney disease: a systematic review and meta-analysis.

Visser W, van de Braak E, de Mik-van Egmond A, van der Burgh A, de Roos N, Jans I J Cachexia Sarcopenia Muscle. 2023; 14(6):2498-2508.

PMID: 37728018 PMC: 10751416. DOI: 10.1002/jcsm.13330.


Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects.

Komaba H Clin Exp Nephrol. 2023; 27(5):395-401.

PMID: 36977891 PMC: 10104924. DOI: 10.1007/s10157-023-02336-y.